MS, Inc.

Far earlier than the mid-winter moon set behind the hills of west Kerry this morning, the morning after news broke that Biogen Idec purchased Tysabri from its partner and inventor of the drug, Elan for a whopping $3.25 Billion (that’s $3,250,000,000), I lay awake trying to fathom the vastness of the news. I am no mathematician on my best days and ever since my attack in August of 2011 I still have an aversion to numbers. Still, the thoughts rumbled in my head. Even at current wholesale prices and using the figures posted by the company itself (that over 99,000 people worldwide have “taken” Tysabri not “are on Tysabri therapy”) I see over 15 years to pay for the purchase. Were I an investor – which I am consciously not an investor in pharmaceutical companies so as not to appear to be swayed by financial gain – I don’t think I’d want to wait 15 years for the return on an investment. Must be something else going on. What; I’ll not speculate for that’s all it would be… but it must be something. Now, several cups of coffee, hours of interweb research and I’m no closer to understanding it all. But I will admit that the whole topic is becoming an irritating raspberry seed in my wisdom tooth. So, I offer to begin (yet another) occasional series on the Life With MS Blog. We’ve a few others topics I post about on an ad hoc, as necessary basis (Life with MS In Box - MS Money Matters - , etc) Today I’d like to introduce an opening for topics under the heade...
Source: Life with MS - Category: Other Conditions Authors: Tags: MS Politics MS pills Tysabri ms and businesses multiple sclerosis drugs Source Type: blogs